TY - JOUR
T1 - A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays
AU - Ni, Yan
AU - Rosier, Bas J.H.M.
AU - van Aalen, Eva A.
AU - Hanckmann, Eva T.L.
AU - Biewenga, Lieuwe
AU - Pistikou, Anna-Maria Makri
AU - Timmermans, Bart
AU - Vu, Chris
AU - Roos, Sophie
AU - Arts, Remco
AU - Li, Wentao
AU - de Greef, Tom F.A.
AU - van Borren, Marcel M G J
AU - van Kuppeveld, Frank J.M.
AU - Bosch, Berend-Jan
AU - Merkx, Maarten
N1 - © 2021. The Author(s).
PY - 2021/7/28
Y1 - 2021/7/28
N2 - Heterogeneous immunoassays such as ELISA have become indispensable in modern bioanalysis, yet translation into point-of-care assays is hindered by their dependence on external calibration and multiple washing and incubation steps. Here, we introduce RAPPID (Ratiometric Plug-and-Play Immunodiagnostics), a mix-and-measure homogeneous immunoassay platform that combines highly specific antibody-based detection with a ratiometric bioluminescent readout. The concept entails analyte-induced complementation of split NanoLuc luciferase fragments, photoconjugated to an antibody sandwich pair via protein G adapters. Introduction of a calibrator luciferase provides a robust ratiometric signal that allows direct in-sample calibration and quantitative measurements in complex media such as blood plasma. We developed RAPPID sensors that allow low-picomolar detection of several protein biomarkers, anti-drug antibodies, therapeutic antibodies, and both SARS-CoV-2 spike protein and anti-SARS-CoV-2 antibodies. With its easy-to-implement standardized workflow, RAPPID provides an attractive, fast, and low-cost alternative to traditional immunoassays, in an academic setting, in clinical laboratories, and for point-of-care applications.
AB - Heterogeneous immunoassays such as ELISA have become indispensable in modern bioanalysis, yet translation into point-of-care assays is hindered by their dependence on external calibration and multiple washing and incubation steps. Here, we introduce RAPPID (Ratiometric Plug-and-Play Immunodiagnostics), a mix-and-measure homogeneous immunoassay platform that combines highly specific antibody-based detection with a ratiometric bioluminescent readout. The concept entails analyte-induced complementation of split NanoLuc luciferase fragments, photoconjugated to an antibody sandwich pair via protein G adapters. Introduction of a calibrator luciferase provides a robust ratiometric signal that allows direct in-sample calibration and quantitative measurements in complex media such as blood plasma. We developed RAPPID sensors that allow low-picomolar detection of several protein biomarkers, anti-drug antibodies, therapeutic antibodies, and both SARS-CoV-2 spike protein and anti-SARS-CoV-2 antibodies. With its easy-to-implement standardized workflow, RAPPID provides an attractive, fast, and low-cost alternative to traditional immunoassays, in an academic setting, in clinical laboratories, and for point-of-care applications.
UR - http://www.scopus.com/inward/record.url?scp=85111496370&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-24874-3
DO - 10.1038/s41467-021-24874-3
M3 - Article
C2 - 34321486
SN - 2041-1723
VL - 12
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 4586
ER -